Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics Inc (DE:F6T)
:F6T
F6T Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.60 - €5.00
Previous CloseN/A
Volume185.00
Average Volume (3M)127.00
Market Cap
€98.24M
Enterprise ValueN/A
Total Cash (Recent Filing)€279.07M
Total Debt (Recent Filing)$85.27M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Jul 30, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding114,633,020
10 Day Avg. Volume0
30 Day Avg. Volume127
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.60Price Target Upside389.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
EarningsFATE reported a net loss per share that was better than the consensus expectation.
Financial PositionThe company ended the quarter with a strong cash position expected to fund operations through the first half of 2027.
Regulatory SupportThe company received RMAT designation for FT819, indicating regulatory support and recognition of the therapy's potential.
Bears Say
Investor SentimentPoor durability of response in the early systemic lupus erythematosus cohorts may be disappointing to investors.
Pipeline DevelopmentAnalyst remains on the fence regarding shares until further details emerge on program timelines.
Potential ConflictsThere is a potential conflict of interest as Wedbush Securities may have a conflict of interest that could affect the objectivity of this report.
---
Options Prices
Currently, No data available
---
Ownership Overview
18.11% Insiders
15.79%
Mutual Funds
0.30% Other Institutional Investors
55.62% Public Companies and
Individual Investors
F6T FAQ
What was Fate Therapeutics Inc’s price range in the past 12 months?
Fate Therapeutics Inc lowest stock price was €0.60 and its highest was €5.00 in the past 12 months.
What is Fate Therapeutics Inc’s market cap?
Fate Therapeutics Inc’s market cap is €98.24M.
When is Fate Therapeutics Inc’s upcoming earnings report date?
Fate Therapeutics Inc’s upcoming earnings report date is Jul 30, 2025 which is in 75 days.
How were Fate Therapeutics Inc’s earnings last quarter?
Fate Therapeutics Inc released its earnings results on May 13, 2025. The company reported -€0.286 earnings per share for the quarter, beating the consensus estimate of -€0.342 by €0.056.
Is Fate Therapeutics Inc overvalued?
According to Wall Street analysts Fate Therapeutics Inc’s price is currently Undervalued.
Does Fate Therapeutics Inc pay dividends?
Fate Therapeutics Inc does not currently pay dividends.
What is Fate Therapeutics Inc’s EPS estimate?
Fate Therapeutics Inc’s EPS estimate is -0.31.
How many shares outstanding does Fate Therapeutics Inc have?
Fate Therapeutics Inc has 114,633,020 shares outstanding.
What happened to Fate Therapeutics Inc’s price movement after its last earnings report?
Fate Therapeutics Inc reported an EPS of -€0.286 in its last earnings report, beating expectations of -€0.342. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Fate Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:F6T
---
Fate Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.60 (389.07% Upside)
€4.60 (389.07% Upside)
Blogger Sentiment
Bullish
DE:F6T Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $31.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.25%
12-Months-Change
Fundamentals
Return on Equity
-49.23%
Trailing 12-Months
Asset Growth
-30.04%
Trailing 12-Months
Company Description
Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
---
F6T Stock 12 Month Forecast
Average Price Target
€4.60
▲(389.07% Upside)
Technical Analysis
Korro Bio
―
ADC Therapeutics
―
Silence Therapeutics
―
Seer
―
4D Molecular Therapeutics
―
---